The purpose of this study is to evaluate the safety and tolerability of RAD001 (Certican) administered to pediatric renal transplant recipients, and to provide additional safety data.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
45
Columbus Children's Hospital
Columbus, Ohio, United States
Dienst Pediatrie UZ Gasthuisberg, Herestraat 49
Leuven, Belgium
Safety and tolerability at 6 and 12 Months as measured by adverse events, laboratory abnormalities and infections.
Efficacy at 6 and 12 Months as measured by rejection, graft loss, death and loss to follow up.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.